C

Capricor Therapeutics
D

CAPR

7.06000
USD
0.59
(9.12%)
مغلق
حجم التداول
44,031
الربح لكل سهم
-2
العائد الربحي
-
P/E
-5
حجم السوق
322,697,202
أصول ذات صلة
A
ADAP
0.01530
(4.60%)
0.34760 USD
A
ARWR
-0.520
(-3.20%)
15.740 USD
C
CRIS
0.01500
(0.82%)
1.84000 USD
I
INO
-0.03500
(-2.33%)
1.47000 USD
K
KURA
-0.23500
(-3.64%)
6.22500 USD
O
OCUL
0.290
(2.43%)
12.210 USD
V
VCEL
0.410
(1.03%)
40.160 USD
المزيد
الأخبار المقالات

العنوان: Capricor Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.